The U.S. National Institutes of Health on Monday ended one clinical trial of Eli Lilly's experimental COVID-19 antibody treatment after finding that the drug, "bamlanivimab, is unlikely to help hospitalized COVID-19 patients recover from this advanced stage of their disease." The trial was suspended Oct. 13 out of "an abundance of caution," but the NIH said Monday it had found no significant safety issue with the monoclonal antibody treatment.
Eli Lilly said it will continue testing bamlanivimab with the NIH on mild or moderately ill COVID-19 patients to see if it reduces hospitalizations and severe symptoms. Eli Lilly is also conducting its own separate trials.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
The secrets of lab-grown chocolateUnder The Radar Chocolate created 'in a Petri dish' could save crisis-hit industry
-
Trade war with China threatens U.S. economyFeature Trump's tariff battle with China is hitting U.S. businesses hard and raising fears of a global recession
-
Corruption: The road to crony capitalismFeature Trump's tariff pause sent the stock market soaring — was it insider trading?
-
Markets notch worst quarter in years as new tariffs loomSpeed Read The S&P 500 is on track for its worst month since 2022 as investors brace for Trump's tariffs
-
Tesla Cybertrucks recalled over dislodging panelsSpeed Read Almost every Cybertruck in the US has been recalled over a stainless steel panel that could fall off
-
Crafting emporium Joann is going out of businessSpeed Read The 82-year-old fabric and crafts store will be closing all 800 of its stores
-
Trump's China tariffs start after Canada, Mexico pausesSpeed Read The president paused his tariffs on America's closest neighbors after speaking to their leaders, but his import tax on Chinese goods has taken effect
-
Chinese AI chatbot's rise slams US tech stocksSpeed Read The sudden popularity of a new AI chatbot from Chinese startup DeepSeek has sent U.S. tech stocks tumbling
-
US port strike averted with tentative labor dealSpeed Read The strike could have shut down major ports from Texas to Maine
-
Biden expected to block Japanese bid for US SteelSpeed Read The president is blocking the $14 billion acquisition of U.S. Steel by Japan's Nippon Steel, citing national security concerns
-
Judges block $25B Kroger-Albertsons mergerSpeed Read The proposed merger between the supermarket giants was stalled when judges overseeing two separate cases blocked the deal
